Breakthrough

Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Posted on by Linda Rider
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy

Turning Level Therapeutics, Inc. SAN DIEGO, May 10, 2022 (Globe NEWSWIRE) — Turning Stage Therapeutics, Inc. (NASDAQ: TPTX), a scientific-phase precision oncology business developing and developing novel focused therapies for most cancers treatment method, these days introduced the U.S. Foodstuff and Drug Administration (Food and drug administration) granted an eighth regulatory designation, and third Breakthrough […]

Read More